Chemistry:LBT-3627
From HandWiki
LBT-3627 is an experimental peptide drug derived from vasoactive intestinal peptide (VIP) that can change the behavior of immune cells so they protect dopamine-producing cells rather than attacking them.[1] The drug is being studied for its potential use for Parkinson's disease.[2]
Function
LBT-3627 specifically targets the VIP2 receptor, unlike VIP.[3] The drug also affects microglia.[1] In addition, LBT-3627 is more durable in the body compared to VIP.[4]
History and development
Scientists at the University of Nebraska Medical Center and Longevity Biotech, Inc. first demonstrated the use of the drug in mouse models.[2][4]
A phase I trial for humans was planned for 2017,[4] but as of 2018 it was still in the preclinical development stage.[5]
References
- ↑ 1.0 1.1 Paddock, Catharine (December 17, 2015). "New drug that protects dopamine cells raises treatment hope for Parkinson's". http://www.medicalnewstoday.com/articles/304212.php.
- ↑ 2.0 2.1 "Pioneering Neuroprotective Results Achieved in Parkinson's Disease Preclinical Studies". December 16, 2015. http://www.prnewswire.com/news-releases/pioneering-neuroprotective-results-achieved-in-parkinsons-disease-preclinical-studies-300193581.html.
- ↑ Azevedo, Margarida (December 21, 2015). "New Drug Candidate Shows Promise in Animal Model of Parkinson's". http://parkinsonsnewstoday.com/2015/12/21/pioneering-neuroprotective-results-achieved-in-parkinsons-disease-preclinical-studies/.
- ↑ 4.0 4.1 4.2 Block, Jonathan (December 17, 2015). "Drug That Protects Dopamine Cells Eyed as Parkinson's Treatment". http://www.psychiatryadvisor.com/neurocognitive-disorders/parkinsons-disease-dopamine-neuroprotective-brain-cells/article/460556/.
- ↑ "Research programme: peptide-based therapeutics - Longevity Biotech". AdisInsight. January 8, 2018. https://adisinsight.springer.com/drugs/800044198. "Highest Development Phases: Preclinical : Neurological disorders; Type 2 diabetes mellitus"
 |  |
